KDIGO provided recommendations on SGLT2 inhibitors and nonsteroidal MRAs in patients with diabetes and CKD.
Where this comes from
- Record sourced from PubMed, PMID 37126811.
- Also identified by DOI 10.7326/J23-0023.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Navaneethan SD, Zoungas S, Caramori ML, et al. <b>Diabetes management in chronic kidney disease: synopsis of the KDIGO 2022 clinical practice guideline update.</b> Ann Intern Med. 2023;176:381-387. 36623286.
Medical subject headings
- Diabetes Mellitus
- Renal Insufficiency, Chronic
- Sodium-Glucose Transporter 2 Inhibitors